Advertisement
Canada markets open in 5 hours 51 minutes

  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • CAD/USD

    0.7318
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    81.24
    +0.41 (+0.51%)
     

  • Bitcoin CAD

    84,191.64
    +1,073.17 (+1.29%)
     

  • CMC Crypto 200

    1,280.77
    -3.02 (-0.23%)
     

  • GOLD FUTURES

    2,326.40
    -4.40 (-0.19%)
     

  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • NASDAQ futures

    20,038.75
    +66.50 (+0.33%)
     

  • VOLATILITY

    12.80
    -0.04 (-0.31%)
     

  • FTSE

    8,280.22
    +32.43 (+0.39%)
     

  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     

  • CAD/EUR

    0.6843
    +0.0011 (+0.16%)
     

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Vericel Corporation
·2 min read
Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com